Inclisiran inhibits hepatic synthesis of proprotein convertase subtilisin–kexin type 9. Previous studies suggest that inclisiran might provide sustained reductions in low-density lipoprotein (LDL) ...
PHILADELPHIA--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced detailed results from ORION-10, the second of three pivotal 18-month low-density lipoprotein cholesterol (LDL-C) ...
Propensity-matched TriNetX analysis (2022–2024) compared 999 inclisiran-treated ASCVD patients on maximal statins with 999 controls using >30 covariates to reduce confounding. Inclisiran was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results